Consumer medicine information

1. Why am I using KINSON?

KINSON contains the active ingredients levodopa and carbidopa. KINSON is used to treat some of the symptoms of Parkinson's disease.
For more information, see Section 1. Why am I using KINSON? in the full CMI.

2. What should I know before I use KINSON?

Do not use if you have ever had an allergic reaction to KINSON or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I use KINSON? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with KINSON and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I use KINSON?

• Your doctor will tell you how many tablets to take each day. Follow all directions given to you by your doctor carefully.

• Swallow the KINSON tablet whole or as half tablets, with a glass of water.

5. What should I know while using KINSON?

6. Are there any side effects?

The most common side effects are nausea, hallucinations, confusion, dizziness, abnormal uncontrolled movements and dry mouth. Serious side effects include blood in the urine, difficult or painful urination, changes in mood, forgetfulness, signs of anaemia such as tiredness and shortness of breath, frequent or worrying infections, bruising or bleeding, fainting, skin changes, numbness or tingling in the feet.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

1 Name of Medicine

Levodopa and carbidopa (as monohydrate).

2 Qualitative and Quantitative Composition

Kinson is a combination of levodopa, the metabolic precursor of dopamine, and carbidopa, an aromatic amino acid decarboxylase inhibitor, for the treatment of Parkinson's disease and syndrome.
Each tablet contains 100 mg of levodopa and 25 mg of carbidopa (as monohydrate) as the active ingredients.
Excipients with known effect. Sulfites.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Kinson tablet: 9 mm flat bevelled-edged yellow tablet debossed LC/2 on one side and 'alpha' on the reverse.

4 Clinical Particulars

4.9 Overdose

Treatment. Management of acute overdosage with combination levodopa/ carbidopa monohydrate is basically the same as management of acute overdosage with levodopa; however, pyridoxine is not effective in reversing the actions of levodopa/ carbidopa monohydrate.
In the event of overdosage, general supportive measures should be employed. Intravenous fluids should be administered judiciously and an adequate airway maintained. Electrocardiographic monitoring should be instituted and the patient carefully observed for the development of arrhythmias; if required, appropriate antiarrhythmic therapy should be given. The possibility that the patient may have taken other drugs as well as combination levodopa/ carbidopa monohydrate should be taken into consideration. To date, no experience has been reported with dialysis; hence its value in overdosage is not known.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. No data available.
Carcinogenicity. No data available.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure. Active ingredient: levodopa. Chemical name: (-)-3-(3,4-dihydroxyphenyl)-L-alanine.
Structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSLEVODO.gif Molecular formula: C₉H₁₁NO₄. Molecular weight: 197.2.
Active ingredient: carbidopa. Chemical name: L-(-)-2-(3,4-dihydroxybenzyl)-2-hydrazino-propionic acid monohydrate.
Structural formula:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSCARMON.gif Molecular formula: C₁₀H₁₄N₂O₄.H₂O. Molecular weight: 244.3.
Levodopa, an aromatic amino acid, is a colourless, crystalline compound, slightly soluble in water and insoluble in alcohol.
Carbidopa, an inhibitor of aromatic amino acid decarboxylase, is a white, crystalline compound, slightly soluble in water.
CAS number. Levodopa: 59-92-7.
Carbidopa: 28860-95-9.

7 Medicine Schedule (Poisons Standard)

S4 (Prescription Only Medicine).

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/KINSONST.gif